Stephen K. Doberstein
2014
In 2014, Stephen K. Doberstein earned a total compensation of $2.1M as Senior Vice President and Chief Scientific Officer at Nektar Therapeutics, a 84% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $311,350 |
|---|---|
| Option Awards | $1,338,390 |
| Salary | $477,583 |
| Other | $11,804 |
| Total | $2,139,128 |
Doberstein received $1.3M in option awards, accounting for 63% of the total pay in 2014.
Doberstein also received $311.4K in non-equity incentive plan, $477.6K in salary and $11.8K in other compensation.
Rankings
In 2014, Stephen K. Doberstein's compensation ranked 4,246th out of 13,032 executives tracked by ExecPay. In other words, Doberstein earned more than 67.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,246 out of 13,032 | 67th |
Division Manufacturing | 1,502 out of 4,967 | 70th |
Major group Chemicals And Allied Products | 494 out of 1,690 | 71st |
Industry group Drugs | 382 out of 1,369 | 72nd |
Industry Pharmaceutical Preparations | 305 out of 1,042 | 71st |
Source: SEC filing on April 30, 2015.
Doberstein's colleagues
We found four more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2014.